Corton Capital Inc. Makes New Investment in Arcturus Therapeutics Holdings Inc. $ARCT

Corton Capital Inc. acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,338 shares of the biotechnology company’s stock, valued at approximately $174,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Diversify Advisory Services LLC bought a new position in Arcturus Therapeutics in the first quarter valued at approximately $191,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at approximately $244,000. ARK Investment Management LLC grew its stake in shares of Arcturus Therapeutics by 3.9% in the first quarter. ARK Investment Management LLC now owns 2,008,480 shares of the biotechnology company’s stock valued at $21,270,000 after buying an additional 74,629 shares in the last quarter. US Bancorp DE increased its holdings in Arcturus Therapeutics by 218.9% during the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,329 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Arcturus Therapeutics during the first quarter worth $161,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Down 4.0%

Arcturus Therapeutics stock opened at $8.93 on Wednesday. The company’s 50-day moving average price is $17.60 and its two-hundred day moving average price is $14.84. The stock has a market cap of $242.54 million, a P/E ratio of -4.00 and a beta of 2.47. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.77. The company had revenue of $28.30 million for the quarter, compared to the consensus estimate of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%. Equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ARCT shares. Zacks Research downgraded shares of Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Leerink Partners reduced their price target on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating for the company in a report on Friday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Wednesday, October 8th. Guggenheim lowered Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. Finally, Wall Street Zen downgraded Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 25th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $31.71.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.